Kiniksa (KNSA) insider report: 39,364-option grant, RSUs, share sales at $33.49-$34.28
Rhea-AI Filing Summary
Ross Moat, Chief Corporate & Commercial Officer of Kiniksa Pharmaceuticals International (KNSA), reported multiple equity transactions on September 1-2, 2025. The filing shows grant and acquisition of restricted share units (RSUs) and a stock option, and reported dispositions of Class A ordinary shares at prices of $33.49 and $34.28. The derivative section shows an option for 39,364 Class A shares and RSUs representing 9,828 Class A shares, each with specified multi-year vesting schedules. Following the reported transactions, the Form 4 lists beneficial ownership figures for Class A ordinary shares in the range shown, with the last reported post-transaction direct ownership of 12,938 Class A ordinary shares. The filing includes detailed vesting terms: option vesting begins September 1, 2025, and RSUs vest over four-year schedules with 25% annual vesting.
Positive
- Detailed vesting schedules disclosed for RSUs and options, providing transparency on when awards become exercisable or convertible.
- Large option grant (39,364 shares) aligns executive incentives with long-term shareholder value given multi-year vesting.
Negative
- Reported share dispositions at $33.49 and $34.28 reduced the reporting person’s immediate beneficial holdings.
- Grants may cause future dilution if options are exercised and RSUs convert to Class A shares over time.
Insights
TL;DR: Insider received compensation in equity and sold some shares; options and RSUs vest over multiple years, modest near-term shareholder impact.
The filing documents routine equity compensation and limited share dispositions by a senior officer. The grant of a 39,364-share option and nearly 9,828 RSUs increases potential future dilution but these awards vest over multi-year schedules, delaying full economic impact. Reported sales at $33.49 and $34.28 realize proceeds and reduce immediate insider shareholdings to the reported post-transaction direct ownership level of 12,938 Class A shares. For investors, this represents standard executive compensation activity rather than a corporate event affecting operations or guidance.
TL;DR: Transactions reflect standard equity-based pay and scheduled vesting; disclosure is complete with vesting timelines and exercised/sold amounts.
The Form 4 provides clear disclosure of awards and dispositions by the reporting person, including specific vesting commencement dates and schedules for RSUs and options. The combination of immediate share dispositions and long-term vesting aligns with common governance practices to balance liquidity and retention. No departures from standard disclosure practices or indications of unusual timing are evident within the filing itself.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Share Unit | 994 | $0.00 | -- |
| Exercise | Class A Ordinary Share | 994 | $0.00 | -- |
| Tax Withholding | Class A Ordinary Share | 481 | $34.28 | $16K |
| Grant/Award | Restricted Share Unit | 9,828 | $0.00 | -- |
| Grant/Award | Share Option | 39,364 | $0.00 | -- |
| Exercise | Restricted Share Unit | 1,741 | $0.00 | -- |
| Exercise | Restricted Share Unit | 1,611 | $0.00 | -- |
| Exercise | Restricted Share Unit | 2,477 | $0.00 | -- |
| Exercise | Class A Ordinary Share | 1,741 | $0.00 | -- |
| Exercise | Class A Ordinary Share | 1,611 | $0.00 | -- |
| Exercise | Class A Ordinary Share | 2,477 | $0.00 | -- |
| Tax Withholding | Class A Ordinary Share | 2,819 | $33.49 | $94K |
Footnotes (1)
- Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2025. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2025. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date September 2, 2021.
AI-generated analysis. How Rhea-AI works. Not financial advice.
